Background Acute myeloid leukemia (AML) with TP53 mutation (m) has poor outcomes even in the contemporary era with median overall survival (OS) of 6-9 months. The only factor that has been shown to improve outc
Introduction Acute myeloid leukemia (AML) with mutated TP53 ( TP53 MT ) is resistant to chemotherapy and has a poor prognosis. Prior reports suggest that DNA methyltransferase inhibitors (DNMTi), such as decitabine and azacitidine, form covalent DNA-DNMT1 adducts and invoke a DNA damage response...
Acute myeloid leukemia (AML) with intrachromosomal amplification of chromosome 21 (iAMP21) is rare and has not been well characterized. We report 13 patients, 7 men and 6 women, with a median age of 65 years. Eleven patients presented with AML with myelodysplasia-related changes, and two pa...
Robert S Ohgami and Daniel A Arber Department of Pathology, Stanford University, Stanford, CA, USA In this study, we evaluate the expression of p53 in core biopsies with acute myeloid leukemia and correlate the level of expression with acute myeloid leukemia subtype, TP53 mutation status, karyoty...
TP53alterationsinacutemyeloidleukemiawithcomplexkaryotypecorrelatewithspecificcopynumberalterations,monosomalkaryotype,anddismaloutcomeFrankGRücker1;RichardFSchlenk1;LarsBullinger1;SabineKayser1;VeronicaTeleanu1;HelenaKett1;MarianneHabdank1;Carla-MariaKugler1;KarlheinzHolzmann1;VerenaIGaidzik1;PeterPaschka1;Gerhard...
The diagnostic entity of acute myeloid leukemia (AML) encompasses a heterogeneous group of diseases whose prognosis differs substantially according to the nature of the underlying molecular lesions and the age of the patient. AML is predominantly a disea
3 and Stefano Cagnin4,5 Abstract Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive ...
2* Abstract Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal hematopoietic stem cell diseases aris- ing from the bone marrow (BM), and approximately 30% of MDS eventually progress to AML, associated with increas- ingly aggressive neoplastic hematopoietic ...
The most common mutations in acute myeloid leukemia (AML) occur in the DNA-binding domain of p53. TP53 mutations are associated with a very poor prognosis and define a unique disease subgroup within AML. TP53-mutated AML often shows limited response to conventional chemotherapy and even allogeneic...
Keywords: MDS; AML; TP53; magrolimab; eprenetapopt 1. Introduction Of all somatic mutations identified in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), TP53 mutations are associated with the most inferior outcomes across independent studies, with a median OS of ...